FILTER

Refine your search with the following facets to narrow down your results.

3 Current news of forbion-capital-partners

image description

Development of a small molecule that inhibits the replication of SARS-CoV-2 and other RNA viruses

Forbion invests USD 2.3M in seed financing of CoviCept Therapeutics

22-Jan-2021 - Forbion, a European life sciences venture capital firm, announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc., a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses. CoviCept’s lead ...

coronaviruses Covid-19 investments +3

Forbion Closes Oversubscribed Fourth Life Sciences VC Fund at EUR 360 million

Investment focus is on new drugs and technologies

02-Oct-2018 - Forbion has announced the final close of its new flagship fund, Forbion IV. The oversubscribed fund closed at EUR 360 million in capital commitments, significantly above its original target of EUR 250 million. Forbion IV, like its predecessor fund, Forbion III, will primarily focus on ...

investments start-ups venture capital

Bristol-Myers Squibb enters agreement to acquire Promedior, Inc.

Providing exclusive right to novel PRM-151 in development for fibrotic diseases

03-Sep-2015 - Bristol-Myers Squibb Company and Promedior, Inc. announced that the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase 2 ...

acquisitions Bristol-Myers Squibb collaborations +3